1455358-06-1

Basic information

• Product Name: 1-(tert-butyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one
• Synonyms: 1-(tert-butyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one;EOS-60901;2H-Pyrrolo[2,3-b]pyridin-2-one, 1-(1,1-dimethylethyl)-1,3-dihydro-
• CAS NO: 1455358-06-1
• Molecular Formula: C₁₁H₁₄N₂O
• Molecular Weight: 190.24166
• Mol File: 1455358-06-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 382.4±37.0 °C(Predicted)
• Appearance: /
• Density: 1.149±0.06 g/cm3(Predicted)
• PKA: 3.69±0.20(Predicted)
• CAS DataBase Reference: 1-(tert-butyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(tert-butyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one(1455358-06-1)
• EPA Substance Registry System: 1-(tert-butyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one(1455358-06-1)

Safety Data

• Hazardous Substances Data: 1455358-06-1(Hazardous Substances Data)

Usage

General Description

1-(tert-butyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one is a chemical compound with the molecular formula C12H17NO, and it is a pyrrolopyridinone derivative. It has a tert-butyl group attached to the nitrogen atom and a carbonyl group attached to the carbon atom, making it a cyclic imide. 1-(tert-butyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one is used in organic synthesis and drug development due to its potential biological activities. It has a molecular weight of 191.27 g/mol and is a white to off-white solid at room temperature. Its chemical structure and properties make it an interesting target for further research and potential applications in pharmaceutical and material science.

Upstream product

• 3430-17-9 2-bromo-3-picoline 
• 1260403-56-2 methyl tert-butyl(3-methylpyridin-2-yl)carbamate 
• 1235305-63-1 N-(tert-butyl)-3-methylpyridin-2-amine 
• 1455358-36-7 C₁₃H₁₆N₂O₃ 

Downstream Products

• 1375541-21-1 (S)-2′-oxo-1′,2′,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[2,3-b]pyridine]-3-carboxylic acid 
• 1455358-25-4 1-(tert-butyl)-3-((5-chloro-3-(hydroxymethyl)pyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one 
• 1455358-27-6 1-(tert-butyl)-3-(2-(chloromethyl)-5-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one 
• 1374248-80-2 (S)-N-((3S,5S,6R)-6-methyl-2-oxo-5-(o-tolyl)-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2’-oxo-l‘,2’,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3’-pyrrolo[2,3-b]pyridine]-3-carboxamide 
• 1374248-83-5 (S)-N-((3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,5-trifluorophenyl)piperidin-3-yl)-2’-oxo-1‘,2’,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3‘-pyrrolo [2,3-b]pyridine]-3-carboxamide 
• 1374248-77-7 (6S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2′-oxo-1′,2′,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[2,3-b]pyridine]-3-carboxamide 

Relevant articles and documents

Asymmetric Dieckmann Condensation towards Spirocyclic Oxindoles Catalyzed by Amino Acid-Derived Phosphonium Salts

An asymmetric Dieckmann condensation towards spirocyclic oxindoles and aza-oxindoles catalyzed by amino acid-derived phosphonium salt has been developed, which expanded the applicability of asymmetric phosphonium salt catalysis in the production of 1,3-dicarbonyl compounds. This reaction is distinguished by its mild conditions (?20 °C), low catalyst loading (3–5 mol%), and broad substrate scope (25 examples). Control experiments revealed that both the catalyst‘s phosphonium skeleton and H-bonding site were required. Product transformations and a gram scale experiment were also carried out. (Figure presented.).

COMPOUNDS

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds;and intermediates useful in the preparation of the compounds.

PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS

The disclosure encompasses a novel process for making piperidinone carboxamide indane and azainane derivatives, having less steps and improved yields as compared to previous synthetic methods for making these compounds, which are CGRP receptor antagonists, useful for the treatment of migrane. Conditions for an amide bond formation between an acid and amine include for example reacting the compounds of Formulae B (after salt break) and C with an amide coupling reagent and optionally an additive and an acid and/or a base in a non-reactive solvent.